Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Actemra IV (tocilizumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

JW Pharma, Roche

Drug class:

IL-6R antagonist

Related drugs:

‹

›

PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab + tocilizumab Sensitive: C3 – Early Trials atezolizumab + tocilizumab Sensitive : C3	atezolizumab + tocilizumab Sensitive: C3 – Early Trials atezolizumab + tocilizumab Sensitive : C3
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	tocilizumab Sensitive: C3 – Early Trials tocilizumab Sensitive : C3	tocilizumab Sensitive: C3 – Early Trials tocilizumab Sensitive : C3
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	tocilizumab Sensitive: C3 – Early Trials tocilizumab Sensitive : C3	tocilizumab Sensitive: C3 – Early Trials tocilizumab Sensitive : C3